Screener
Xeris Biopharma Holdings, Inc. XERS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
FAQ
- What is Xeris Biopharma Holdings, Inc.'s total liabilities?
- Xeris Biopharma Holdings, Inc. (XERS) reported total liabilities of $421.64M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s total liabilities changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s total liabilities increased by 19.1% year-over-year, from $353.99M to $421.64M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s total liabilities has grown at a 24.2% compound annual growth rate (CAGR), from $125.39M to $369.84M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Xeris Biopharma Holdings, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude